IN2012DE00594A - - Google Patents

Download PDF

Info

Publication number
IN2012DE00594A
IN2012DE00594A IN594DE2012A IN2012DE00594A IN 2012DE00594 A IN2012DE00594 A IN 2012DE00594A IN 594DE2012 A IN594DE2012 A IN 594DE2012A IN 2012DE00594 A IN2012DE00594 A IN 2012DE00594A
Authority
IN
India
Prior art keywords
ask1
nef
interaction
hiv
host
Prior art date
Application number
Other languages
English (en)
Inventor
Raj Kamal Tripathi
Balawant Kumar
Ravishankar Ramachandran
Jitendra Kumar Tripathi
Smriti Bhaduria
Jimut Kanti Ghosh
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Priority to PCT/IB2013/051641 priority Critical patent/WO2013128418A2/en
Priority to US14/382,428 priority patent/US9327009B2/en
Priority to IN594DE2012 priority patent/IN2012DE00594A/en
Publication of IN2012DE00594A publication Critical patent/IN2012DE00594A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
IN594DE2012 2012-03-02 2013-03-01 IN2012DE00594A (enExample)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/IB2013/051641 WO2013128418A2 (en) 2012-03-02 2013-03-01 Peptide inhibitors as novel anti-hiv therapeutics
US14/382,428 US9327009B2 (en) 2012-03-02 2013-03-01 Peptide inhibitors as novel anti-HIV therapeutics
IN594DE2012 IN2012DE00594A (enExample) 2012-03-02 2013-03-01

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN594DE2012 IN2012DE00594A (enExample) 2012-03-02 2013-03-01

Publications (1)

Publication Number Publication Date
IN2012DE00594A true IN2012DE00594A (enExample) 2015-08-21

Family

ID=48326351

Family Applications (1)

Application Number Title Priority Date Filing Date
IN594DE2012 IN2012DE00594A (enExample) 2012-03-02 2013-03-01

Country Status (3)

Country Link
US (1) US9327009B2 (enExample)
IN (1) IN2012DE00594A (enExample)
WO (1) WO2013128418A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018094964A1 (zh) * 2016-11-25 2018-05-31 武汉大学 一种以凋亡信号调节激酶1n端二聚化为靶点筛选用于治疗脂肪性肝炎药物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057272A1 (en) * 1998-05-04 1999-11-11 The Mount Sinai School Of Medicine Of New York University Peptide inhibitors of hiv replication
DE19820224A1 (de) * 1998-05-06 1999-12-09 Markus Schott Bindungspartner und Verfahren zur kompetitiven Hemmung der Bindung zwischen NEF-Protein und Calmodulin, sowie Mittel und Verwendung bei HIV-Erkrankungen
EP1225907A4 (en) * 1999-10-05 2005-06-22 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
CN1635876A (zh) * 2000-02-04 2005-07-06 杜克大学 人免疫缺陷病毒疫苗
WO2004048565A1 (ja) * 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited アポトーシス関連蛋白質およびその用途

Also Published As

Publication number Publication date
WO2013128418A2 (en) 2013-09-06
US20150182581A1 (en) 2015-07-02
WO2013128418A3 (en) 2014-01-30
US9327009B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
Wallace et al. Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
EA024121B9 (ru) Композиции эндорибонуклеаз и способы их использования
EP4368728A3 (en) Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX2020010692A (es) Metodos y sistemas para la deteccion rapida de microorganismos con el uso de bacteriofago recombinante.
NZ705745A (en) Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
MX2022007933A (es) Compuestos de polimetino y su uso como etiquetas fluorescentes.
WO2013188638A3 (en) Endoribonucleases and methods of use thereof
CA2884084C (en) Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
NZ728437A (en) Methods for increasing cas9-mediated engineering efficiency
MX384919B (es) Receptores de células t de kras anti-mutado.
SG10201809566SA (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
GB201200658D0 (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
EP4361290A3 (en) Compositions and methods for detecting a biological contaminant
IN2015DN02793A (enExample)
PH12015502421A1 (en) Artificial transcription factors engineered to overcome endosomal entrapment
BR112017003559A2 (pt) métodos para a detecção rápida e sensível de mutações de locais-alvo
MX373329B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
EP4321867A3 (en) Probes for improved melt discrimination and multiplexing in nucleic acid assays
AR092879A1 (es) Proteinas de fusion de g3p como agentes de union a amiloide
EP4556571A3 (en) Redox labeled oligonucleotide probes and their use
EP4067507A3 (en) Pna probes, kits and methods for detecting genotypes of human papillomavirus
IN2014CN02963A (enExample)
CA3010199A1 (en) Method of direct target sequencing using nuclease protection